KR101766502B1 - 인돌 화합물 및 그의 의약 용도 - Google Patents
인돌 화합물 및 그의 의약 용도 Download PDFInfo
- Publication number
- KR101766502B1 KR101766502B1 KR1020127016311A KR20127016311A KR101766502B1 KR 101766502 B1 KR101766502 B1 KR 101766502B1 KR 1020127016311 A KR1020127016311 A KR 1020127016311A KR 20127016311 A KR20127016311 A KR 20127016311A KR 101766502 B1 KR101766502 B1 KR 101766502B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- substituted
- compound
- alkoxy
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FAPOYQXIBRBNJW-UHFFFAOYSA-O CC(C)(CC1)CC([NH3+])=C1C(c1cc(ccc(N(C)C(C)=O)c2)c2[nH]1)=N Chemical compound CC(C)(CC1)CC([NH3+])=C1C(c1cc(ccc(N(C)C(C)=O)c2)c2[nH]1)=N FAPOYQXIBRBNJW-UHFFFAOYSA-O 0.000 description 1
- CKGURMJZTVPJFU-UHFFFAOYSA-N CC(C)(CC1)Cc2c1c(-c([nH]c1c3)cc1ccc3NC)n[nH]2 Chemical compound CC(C)(CC1)Cc2c1c(-c([nH]c1c3)cc1ccc3NC)n[nH]2 CKGURMJZTVPJFU-UHFFFAOYSA-N 0.000 description 1
- UESJEBGRGGURRJ-YSGASBTCSA-N CC(C)(CC1)Cc2c1c(-c([n](COCC[SiH](C)C)c1c3)cc1ccc3/N=C\C)n[n]2COCC[Si](C)(C)C Chemical compound CC(C)(CC1)Cc2c1c(-c([n](COCC[SiH](C)C)c1c3)cc1ccc3/N=C\C)n[n]2COCC[Si](C)(C)C UESJEBGRGGURRJ-YSGASBTCSA-N 0.000 description 1
- 0 CC(C)(CC1)Cc2c1c(-c1cc(ccc(N(C)C(C)=O)c3)c3[n]1COCC*)n[n]2COCC[Si](C)(C)C Chemical compound CC(C)(CC1)Cc2c1c(-c1cc(ccc(N(C)C(C)=O)c3)c3[n]1COCC*)n[n]2COCC[Si](C)(C)C 0.000 description 1
- VLSUABJDLLMXJS-UHFFFAOYSA-N CC(CO)(CC1)Cc2c1c(-c([nH]c1c3)cc1ccc3N(C)C(CN(CCCC1)C1=O)=O)n[nH]2 Chemical compound CC(CO)(CC1)Cc2c1c(-c([nH]c1c3)cc1ccc3N(C)C(CN(CCCC1)C1=O)=O)n[nH]2 VLSUABJDLLMXJS-UHFFFAOYSA-N 0.000 description 1
- NIBMSVVMFOAWIZ-UHFFFAOYSA-N CC(CO)(CC1)Cc2c1c(-c([n](COCC[SiH](C)C)c1c3)cc1ccc3N(C)C(CN(CCCC1)C1=O)=O)n[n]2COCC[Si](C)(C)C Chemical compound CC(CO)(CC1)Cc2c1c(-c([n](COCC[SiH](C)C)c1c3)cc1ccc3N(C)C(CN(CCCC1)C1=O)=O)n[n]2COCC[Si](C)(C)C NIBMSVVMFOAWIZ-UHFFFAOYSA-N 0.000 description 1
- NLZYZSHOSOLTAA-UHFFFAOYSA-N CC(CO)(CCC1)CC11OCCO1 Chemical compound CC(CO)(CCC1)CC11OCCO1 NLZYZSHOSOLTAA-UHFFFAOYSA-N 0.000 description 1
- XJGFNJZYOIZNEW-UHFFFAOYSA-N CC(CO)NC(c1cc([n](COCC[SiH](C)C)c(-c2n[n](COCC[Si](C)(C)C)c3c2CCC(C)(C)C3)c2)c2cc1)=O Chemical compound CC(CO)NC(c1cc([n](COCC[SiH](C)C)c(-c2n[n](COCC[Si](C)(C)C)c3c2CCC(C)(C)C3)c2)c2cc1)=O XJGFNJZYOIZNEW-UHFFFAOYSA-N 0.000 description 1
- RTQSZFGSJOYNTH-UHFFFAOYSA-N CC(COCc1ccccc1)(CCC1)CC11OCCO1 Chemical compound CC(COCc1ccccc1)(CCC1)CC11OCCO1 RTQSZFGSJOYNTH-UHFFFAOYSA-N 0.000 description 1
- XCOPYDBCXYNXRE-UHFFFAOYSA-N CC(CO[Si](C(C)(C)C)(c1ccccc1)c1ccccc1)NC(c1cc([n](COCC[SiH](C)C)c(-c2n[n](COCC[Si](C)(C)C)c3c2CCC(C)(C)C3)c2)c2cc1)=O Chemical compound CC(CO[Si](C(C)(C)C)(c1ccccc1)c1ccccc1)NC(c1cc([n](COCC[SiH](C)C)c(-c2n[n](COCC[Si](C)(C)C)c3c2CCC(C)(C)C3)c2)c2cc1)=O XCOPYDBCXYNXRE-UHFFFAOYSA-N 0.000 description 1
- ZZZXGCPVQQOASC-INIZCTEOSA-N C[C@@H](C(N(C)c1ccc(cc(-c2n[nH]c3c2CCC(C)(C)C3)[nH]2)c2c1)=O)N1CCOCC1 Chemical compound C[C@@H](C(N(C)c1ccc(cc(-c2n[nH]c3c2CCC(C)(C)C3)[nH]2)c2c1)=O)N1CCOCC1 ZZZXGCPVQQOASC-INIZCTEOSA-N 0.000 description 1
- WEJKUVSYIGOBAR-LURJTMIESA-N C[C@@H](C(O)=O)N1CCOCC1 Chemical compound C[C@@H](C(O)=O)N1CCOCC1 WEJKUVSYIGOBAR-LURJTMIESA-N 0.000 description 1
- CDSJDFVITCHACO-UHFFFAOYSA-N O=C(CN(CCOC1)C1=O)OCc1ccccc1 Chemical compound O=C(CN(CCOC1)C1=O)OCc1ccccc1 CDSJDFVITCHACO-UHFFFAOYSA-N 0.000 description 1
- SZUPCAZDKKJKEX-UHFFFAOYSA-N OC(CN(CCOC1)C1=O)=O Chemical compound OC(CN(CCOC1)C1=O)=O SZUPCAZDKKJKEX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009268040 | 2009-11-25 | ||
| JPJP-P-2009-268040 | 2009-11-25 | ||
| PCT/JP2010/070988 WO2011065402A1 (ja) | 2009-11-25 | 2010-11-25 | インドール化合物及びその医薬用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120096540A KR20120096540A (ko) | 2012-08-30 |
| KR101766502B1 true KR101766502B1 (ko) | 2017-08-08 |
Family
ID=44066507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127016311A Active KR101766502B1 (ko) | 2009-11-25 | 2010-11-25 | 인돌 화합물 및 그의 의약 용도 |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US8299070B2 (https=) |
| EP (3) | EP2505586B1 (https=) |
| JP (6) | JP5734628B2 (https=) |
| KR (1) | KR101766502B1 (https=) |
| CN (1) | CN102712624B (https=) |
| AR (1) | AR079164A1 (https=) |
| AU (1) | AU2010323579C1 (https=) |
| BR (1) | BR112012012529B1 (https=) |
| CA (1) | CA2781660C (https=) |
| CL (1) | CL2012001328A1 (https=) |
| CO (1) | CO6541645A2 (https=) |
| CY (1) | CY1117559T1 (https=) |
| DK (1) | DK2505586T3 (https=) |
| ES (1) | ES2572935T3 (https=) |
| HR (1) | HRP20160579T1 (https=) |
| HU (1) | HUE028016T2 (https=) |
| IL (1) | IL220009A (https=) |
| ME (1) | ME02447B (https=) |
| MX (1) | MX2012006017A (https=) |
| MY (1) | MY161095A (https=) |
| NZ (1) | NZ600840A (https=) |
| PE (1) | PE20121358A1 (https=) |
| PH (1) | PH12012501021A1 (https=) |
| PL (1) | PL2505586T3 (https=) |
| PT (1) | PT2505586E (https=) |
| RS (1) | RS54910B1 (https=) |
| RU (1) | RU2556216C2 (https=) |
| SI (1) | SI2505586T1 (https=) |
| SM (1) | SMT201600258B (https=) |
| TW (1) | TWI491591B (https=) |
| WO (1) | WO2011065402A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
| CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
| CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
| SG11201503459SA (en) | 2012-11-02 | 2015-06-29 | Pharmacyclics Inc | Tec family kinase inhibitor adjuvant therapy |
| CN103804364A (zh) * | 2012-11-06 | 2014-05-21 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
| CN103800328A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804291A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804361A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103800337A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103800340A (zh) * | 2012-11-09 | 2014-05-21 | 韩冰 | 一类治疗青光眼的化合物及其用途 |
| CN103804351A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN103804302A (zh) * | 2012-11-14 | 2014-05-21 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN103804363A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN103804272A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN104628657A (zh) * | 2013-11-06 | 2015-05-20 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
| WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
| AR099936A1 (es) * | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
| EP3165525B1 (en) * | 2014-07-04 | 2019-09-04 | Japan Tobacco, Inc. | Method for producing indole compound |
| WO2016010108A1 (ja) * | 2014-07-18 | 2016-01-21 | 塩野義製薬株式会社 | 含窒素複素環誘導体およびそれらを含有する医薬組成物 |
| CN104356086A (zh) * | 2014-11-28 | 2015-02-18 | 湖南科技大学 | 一种适于工业生产3-吗啉酮的制备方法 |
| MX2020012644A (es) * | 2018-05-25 | 2021-01-29 | Japan Tobacco Inc | Metodo para tratar dolor o cistitis intersticial utilizando compuesto de indol. |
| WO2019225740A1 (ja) | 2018-05-25 | 2019-11-28 | 日本たばこ産業株式会社 | インドール化合物を含む多発性硬化症の治療又は予防剤 |
| EP3804727B1 (en) * | 2018-05-25 | 2023-10-11 | Japan Tobacco Inc. | Indol-containing compound for use in the treatment of the nephrotic syndrome |
| MX2022007518A (es) | 2019-12-20 | 2022-09-19 | Pfizer | Derivados bencimidazol. |
| KR102270026B1 (ko) * | 2020-01-31 | 2021-06-28 | 현대약품 주식회사 | (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법 |
| JP2023552863A (ja) * | 2020-12-15 | 2023-12-19 | ファイザー・インク | ベンゾイミダゾール誘導体および皮膚疾患の処置のためのｉｔｋの阻害剤としてのそれらの使用 |
| EP4263538A1 (en) * | 2020-12-15 | 2023-10-25 | Pfizer Inc. | Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease |
| WO2022235715A1 (en) * | 2021-05-03 | 2022-11-10 | Nurix Therapeutics, Inc. | Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use |
| CA3217892A1 (en) * | 2021-05-03 | 2022-11-10 | Joel Mcintosh | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use |
| TW202315618A (zh) * | 2021-06-11 | 2023-04-16 | 美商愛德亞生物科學公司 | 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物 |
| US20250002489A1 (en) * | 2021-10-19 | 2025-01-02 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading itk via ubiquitin proteosome pathway |
| AU2024251390A1 (en) * | 2023-04-13 | 2025-11-27 | Danatlas Pharmaceuticals Co., Ltd. | Thiadiazolone derivatives, compositions and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003231687A (ja) * | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| WO2008135785A1 (en) * | 2007-05-04 | 2008-11-13 | Astrazeneca Ab | 9- (pyrazol- 3 -yl) - 9h- purine-2 -amine and 3- (pyraz0l-3-yl) -3h-imidaz0 [4, 5-b] pyridin-5-amine derivatives and their use for the treatment of cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US953411A (en) * | 1908-09-02 | 1910-03-29 | Erastus De Moulin | Trick weight-lifting machine. |
| JP5039268B2 (ja) * | 2001-10-26 | 2012-10-03 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用 |
| AU2003235741B8 (en) * | 2002-01-07 | 2009-01-15 | Eisai R&D Management Co., Ltd. | Deazapurines and uses thereof |
| FR2854159B1 (fr) * | 2003-04-25 | 2008-01-11 | Aventis Pharma Sa | Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr |
| US20050032869A1 (en) * | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| RS51846B (sr) * | 2003-09-08 | 2012-02-29 | Aventis Pharmaceuticals Inc. | Tienopirazoli |
| WO2006112479A1 (ja) * | 2005-04-19 | 2006-10-26 | Kyowa Hakko Kogyo Co., Ltd. | 含窒素複素環化合物 |
| JP2009520831A (ja) * | 2005-12-20 | 2009-05-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｅｃキナーゼインヒビター |
| GB0602178D0 (en) | 2006-02-03 | 2006-03-15 | Merck Sharp & Dohme | Therapeutic treatment |
| JP5255559B2 (ja) * | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
| MX2008014450A (es) * | 2006-05-18 | 2009-03-09 | Mannkind Corp | Inhibidores de cinasa intracelular. |
| JPWO2008047831A1 (ja) * | 2006-10-17 | 2010-02-25 | 協和発酵キリン株式会社 | Ｊａｋ阻害剤 |
| CA2668744C (en) | 2006-11-17 | 2015-09-15 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
| JP2009268040A (ja) | 2008-04-23 | 2009-11-12 | Teruhiko Daiho | ループアンテナ装置 |
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
-
2010
- 2010-11-24 US US12/954,438 patent/US8299070B2/en active Active
- 2010-11-25 TW TW099140715A patent/TWI491591B/zh active
- 2010-11-25 MY MYPI2012002292A patent/MY161095A/en unknown
- 2010-11-25 PH PH1/2012/501021A patent/PH12012501021A1/en unknown
- 2010-11-25 KR KR1020127016311A patent/KR101766502B1/ko active Active
- 2010-11-25 PE PE2012000713A patent/PE20121358A1/es active IP Right Grant
- 2010-11-25 JP JP2010262058A patent/JP5734628B2/ja active Active
- 2010-11-25 CN CN201080062299.3A patent/CN102712624B/zh active Active
- 2010-11-25 ME MEP-2016-107A patent/ME02447B/me unknown
- 2010-11-25 EP EP10833248.7A patent/EP2505586B1/en active Active
- 2010-11-25 SI SI201031188A patent/SI2505586T1/sl unknown
- 2010-11-25 MX MX2012006017A patent/MX2012006017A/es active IP Right Grant
- 2010-11-25 AU AU2010323579A patent/AU2010323579C1/en active Active
- 2010-11-25 NZ NZ600840A patent/NZ600840A/en unknown
- 2010-11-25 EP EP16158053.5A patent/EP3059234A1/en not_active Withdrawn
- 2010-11-25 DK DK10833248.7T patent/DK2505586T3/en active
- 2010-11-25 WO PCT/JP2010/070988 patent/WO2011065402A1/ja not_active Ceased
- 2010-11-25 ES ES10833248.7T patent/ES2572935T3/es active Active
- 2010-11-25 BR BR112012012529-0A patent/BR112012012529B1/pt active IP Right Grant
- 2010-11-25 EP EP20189306.2A patent/EP3766877A1/en not_active Withdrawn
- 2010-11-25 HR HRP20160579TT patent/HRP20160579T1/hr unknown
- 2010-11-25 RS RS20160385A patent/RS54910B1/sr unknown
- 2010-11-25 AR ARP100104362A patent/AR079164A1/es active IP Right Grant
- 2010-11-25 RU RU2012126129/04A patent/RU2556216C2/ru active
- 2010-11-25 PL PL10833248.7T patent/PL2505586T3/pl unknown
- 2010-11-25 CA CA2781660A patent/CA2781660C/en active Active
- 2010-11-25 HU HUE10833248A patent/HUE028016T2/en unknown
- 2010-11-25 PT PT108332487T patent/PT2505586E/pt unknown
-
2012
- 2012-05-23 CL CL2012001328A patent/CL2012001328A1/es unknown
- 2012-05-24 IL IL220009A patent/IL220009A/en active IP Right Grant
- 2012-06-22 CO CO12105036A patent/CO6541645A2/es active IP Right Grant
- 2012-09-26 US US13/627,047 patent/US20130116240A1/en not_active Abandoned
-
2015
- 2015-04-15 JP JP2015083457A patent/JP2015172051A/ja not_active Ceased
-
2016
- 2016-05-26 CY CY20161100462T patent/CY1117559T1/el unknown
- 2016-08-03 SM SM201600258T patent/SMT201600258B/it unknown
- 2016-10-20 JP JP2016205949A patent/JP2017039761A/ja not_active Ceased
- 2016-10-28 US US15/337,583 patent/US20170267662A1/en not_active Abandoned
-
2018
- 2018-01-12 US US15/869,250 patent/US20180362506A1/en not_active Abandoned
- 2018-06-13 JP JP2018112445A patent/JP2018158935A/ja active Pending
-
2019
- 2019-09-19 US US16/575,724 patent/US20200255408A1/en not_active Abandoned
-
2020
- 2020-02-04 JP JP2020017065A patent/JP2020079276A/ja not_active Ceased
- 2020-09-23 US US17/029,642 patent/US20210284627A1/en not_active Abandoned
-
2021
- 2021-03-03 JP JP2021033138A patent/JP2021091718A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003231687A (ja) * | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| WO2008135785A1 (en) * | 2007-05-04 | 2008-11-13 | Astrazeneca Ab | 9- (pyrazol- 3 -yl) - 9h- purine-2 -amine and 3- (pyraz0l-3-yl) -3h-imidaz0 [4, 5-b] pyridin-5-amine derivatives and their use for the treatment of cancer |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101766502B1 (ko) | 인돌 화합물 및 그의 의약 용도 | |
| KR20060087598A (ko) | Ｎ-[헤테로아릴(피페리딘-2-일)메틸]벤즈아미드의 유도체,그의 제조 방법 및 치료법에서의 그의 용도 | |
| JP6250667B2 (ja) | 新しい抗菌化合物 | |
| CA2842526C (en) | Antibacterial homopiperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones | |
| KR20050121681A (ko) | 면역조절 헤테로고리 화합물 | |
| WO2017140269A1 (zh) | 一类取代的氨基六元氮杂环类化合物及其制备和用途 | |
| JP6250668B2 (ja) | 新しい抗菌化合物 | |
| HK1174025B (en) | Indole compound and pharmaceutical use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| FPAY | Annual fee payment |
Payment date: 20200630 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| FPAY | Annual fee payment |
Payment date: 20210629 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20220615 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 9 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R14-asn-PN2301 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R14-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |